Ontrak to Report 2023 First Quarter Financial Results on May 10, 2023
HENDERSON, Nev.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled…
News
Wolfspeed Reports Financial Results for the Third Quarter of Fiscal Year 2023
Year-over-year Quarterly Revenue Growth of 22 Percent; Design-Ins Totaling $1.7 Billion DURHAM, N.C.–(BUSINESS WIRE)–Wolfspeed, Inc….
Align Technology Announces First Quarter 2023 Financial Results
Delivers revenue and EPS ahead of expectations, with total Invisalign® patients treated surpassing 15 million…
POSaBIT Reports Fourth Quarter and Full-Year 2022 Financial Results
POSaBIT continues streak of doubling, or nearly doubling, revenue for 5 consecutive years Raises FY…
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella, Inc. www.nexcella.com Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in…
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella, Inc. www.nexcella.com Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in…
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL)…
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
Nexcella Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in light chain (AL)…
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with…
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
Posters will feature preliminary Phase 1b combination data for potential best-in-class ERK1/2 inhibitor ERAS-007 with…
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
WESTPORT, Conn., April 26, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage…
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
Triggers milestone payment of approximately $0.3 million ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) —…
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
Triggers milestone payment of approximately $0.3 million ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) —…
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,…
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,…
Travere Therapeutics to Report First Quarter 2023 Financial Results
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
Travere Therapeutics to Report First Quarter 2023 Financial Results
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…